Incidence and case fatality rate of COVID‐19 in patients with inflammatory articular diseases

Abstract

Objective To describe the incidence and fatality of coronavirus disease 2019 (COVID‐19) and identify risk factors to fatality in patients with inflammatory articular diseases (IAD). Methods This is a cross‐sectional observational study of IAD patients and COVID‐19 with controls matched for age, sex, and RT‐PCR. A control group was used to compare the cumulative incidence (CI) and case fatality rate (CFR). The main outcomes of the study were CI and CFR. Other variables included comorbidities, treatments, and characteristics of the COVID‐19. Multiple logistic regression analysis was performed to investigate risk factors for fatality in patients with IAD. Results Of the 1537 patients who fulfilled the inclusion criteria, 23/1537 (1.49%) had IAD 13 (0.8%) had rheumatoid arthritis (RA), 5 psoriatic arthritis (PsA) (0.3%) and 5 axial spondyloarthritis (0.3%). There were no significant differences in CI of COVID‐19 and CFR in patients with IAD compared with COVID‐19 patients without IAD. In RT‐PCR positive patients, the CI of COVID‐19 in PsA and AS was higher. Of the 23 IAD patients, 2 RA patients (8.6%) died. The patients did no show characteristics of the COVID‐19 disease different from the population. In multivariate analysis, the factor associated with fatality in patients with IAD was older age (OR [95% CI], 1.1 [1.0‐1.2]). Conclusion COVID‐19 CI, fatality rate and other features do not seem to be increased in IAD patients. Older age was associated with fatality in patients with IAD.

COVID-19 related risk of in-hospital death in Silesia, Poland

“…The mean age at death of our COVID-19 patients is similar to that reported in other studies [6,7]. Experience obtained during the Italian epidemics points to age as one of the most important risk factors of COVID-19 mortality [20], and this conclusion is supported by findings from Spain [21].…”

Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis

“…Meta-analysis of fourteen studies [23][24][25][26][27][28][29][30][31][32][33][34][35][36] showed that patients with RD had a significantly higher risk of developing COVID-19 than the general population (OR = 1.53, 95% CI 1.24-1.88, P = 0.000; I 2 = 62.4%, P = 0.001) ( Fig. 2).…”

“…Seven studies assessed the risk of death from COVID-19 in RD patients and included a quantitative synthesis [27,[34][35][36][38][39][40]. The results showed that there was no higher risk of death due to COVID-19 in patients with RD compared with reference population (OR = 1.29, 95% CI 0.84-1.97, P = 0.248; I 2 = 0%, P = 0.495) (Fig.…”

“…We included three studies [36,38,46], including eleven variables associated with severe COVID-19 (Supplemental Table S4). Not all variables were included in the metaanalysis as not all studies presented data that could be used in models.…”

Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence

“… Baniandré s-Rodr í guez et al, 2021 , Brazzelli et al, 2020 , Costantino et al, 2020 , Damiani et al, 2020 , de Wijs et al, 2020 , Favalli et al, 2020 , Feldmann et al, 2020 , Ferri et al, 2020 , Fougerousse et al, 2020 , Fredi et al, 2020 , Georgakopoulos and Yeung, 2020a , Georgakopoulos et al, 2020b , Gianfrancesco et al, 2020 , Gisondi et al, 2020a , Gisondi et al, 2020b , Hasseli et al, 2020 , Lima et al, 2020 , Mena Vá zquez et al, 2020 , Montero et al, 2020 , Pablos et al, 2020 , Piaserico et al, 2020 , Pirro et al, 2020 , Rodrí guez-Villa Lario et al, 2020 , Stefanini, 2020 , Vispi et al, 2020 .…”